Skip to main content
Equibles

Melissa Epperly

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Melissa Epperly

Melissa Epperly was last confirmed as CFO at Zentalis Pharmaceuticals, Inc. (ZNTL) in a filing dated April 29, 2024. Earlier roles on record: CFO at Zentalis Pharmaceuticals, Inc. (ZNTL) until April 5, 2024. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed April 11, 2024 that Melissa Epperly resigned as Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective April 5, 2024. The proxy statement of Zentalis Pharmaceuticals, Inc. reports total compensation of $5,631,323 for Melissa Epperly in fiscal 2023, including a base salary of $516,372. Disclosed compensation is on record for 3 fiscal years.

“On April 5, 2024, Melissa Epperly resigned as Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”), effective immediately (the “Transition Date”).”
Zentalis Pharmaceuticals, Inc. Form 8-K, filed April 11, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Zentalis Pharmaceuticals, Inc. (ZNTL) $516,372 $5,631,323
2022 Zentalis Pharmaceuticals, Inc. (ZNTL) $487,143 $4,026,248
2021 Zentalis Pharmaceuticals, Inc. (ZNTL) $419,832 $2,336,683

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.